Pinealon

01 · What it is

Pinealon has the smallest evidence base of the four St Petersburg bioregulators in this family, the most specific mechanistic claim among them, and a literature concentrated so tightly in one Russian-language journal that most of it cannot be checked by an English-language reader.

Pinealon is the tripeptide L-lysyl-L-glutamyl-L-aspartate, written KED throughout the group’s later papers. Three amino acids. Like Vilon, it comes out of the programme at the St Petersburg Institute of Bioregulation and Gerontology, and like Vilon its proposed mechanism is that a peptide this small enters the cell nucleus and binds DNA directly.

A naming trap has to be cleared first, because the search results for this compound are contaminated by it. Several frequently cited papers concern Lys-Glu-Asp-Gly (KEDG) and Lys-Glu-Asp-Trp-NH2 (KEDW) — four-residue peptides that differ from Pinealon by an added residue and are separate compounds in the same programme ^2,6,8,15. The thyroid and thymus work in hypophysectomised birds is KEDG work, not KED work ^2,6,15. This guide keeps them apart and cites them only as adjacent context, never as evidence about Pinealon.

The strongest single paper is the 2011 cell viability study, and it is worth noting who is on it. Pinealon increased cell viability by suppressing free radical levels and activating proliferative processes, published in Rejuvenation Research with Alexander Boldyrev — a Moscow State University biochemist known for work on carnosine and oxidative stress, not a member of the St Petersburg group ⁷. That is partial external involvement in the central in vitro result.

The animal work is almost entirely rat brains under stress. Short peptides given before carotid artery occlusion affected behaviour and caspase-3 activity in the brains of old rats ⁵; peptide geroprotectors affected navigation learning and caspase-3 in brain structures of rats of different ages ¹⁴; Pinealon and Cortexin affected behaviour and neurochemical processes in 18-month-old rats under hypoxia and hypothermia ¹⁷. Pinealon protected rat offspring from prenatal hyperhomocysteinaemia ¹⁰. Antihypoxic properties of short peptides were examined as a class ^1,3.

The human record is two Russian-language reports. One concerns peptide correction of neurotic disorders among professional truck drivers, tagged by PubMed as a clinical trial ¹¹; the other concerns the effect of synthetic peptides on ageing in patients with chronic polymorbidity and organic brain syndrome in remission ¹⁶. This guide has read neither. Both are in Russian, neither abstract is indexed, and the Early Clinical grade below rests on a database tag and a title.

That is an unusually weak foundation for a grade, and it is stated here rather than in a footnote.

02 · Evidence at a glance

Evidence grade

Early Clinical — two indexed human reports, one PubMed-tagged as a clinical trial; neither read for this guide ^11,16

Structure

Lys-Glu-Asp, a tripeptide, written KED

Not to be confused with

KEDG (Lys-Glu-Asp-Gly) and KEDW (Lys-Glu-Asp-Trp-NH2) — separate four-residue compounds ^2,6,8,15

Proposed mechanism

Nuclear penetration and sequence-preferential DNA binding ^8,21

Strongest in vitro result

Increased cell viability via free radical suppression, with partial external authorship ⁷

Principal animal model

Rat brain under hypoxia, ischaemia or hypothermia ^5,10,14,17

Indexed records (all names)

~71, many of them false matches

Human reports

Two, both Russian-language ^11,16

Randomised controlled trials

None identified

Human pharmacokinetics

None

Approval status

Not approved in the US or EU; Russian status not verified for this guide

03 · Mechanism of action

The DNA-binding proposal

Pinealon’s mechanism, as the developing group states it, is the same proposal made for Vilon and Epitalon: a peptide of two to four residues is small enough to cross the nuclear envelope and bind DNA at preferred sequences, acting as a transcriptional regulator rather than through a cell-surface receptor.

The supporting evidence is indirect but physical. Fluorescence-labelled short peptides penetrated the nucleus in HeLa cells and interacted specifically with deoxyribooligonucleotides and DNA in vitro, in work published with a Moscow State University DNA methylation group ⁸. Separately, a physical chemistry group at St Petersburg State University examined the role of mono- and divalent ions in the interaction between the related tripeptide Glu-Asp-Arg and DNA ²¹ — a study of the binding itself rather than of any biological consequence, conducted by people with no stake in the compounds.

Two lines of physical evidence that short peptides of this class associate with DNA. Neither shows that Pinealon does anything to a gene, and neither addresses the specificity problem: a three-residue peptide cannot recognise enough bases to distinguish one genomic site from thousands.

Oxidative stress and cell viability

The clearest cellular result is that Pinealon increased cell viability by suppressing free radical levels and activating proliferative processes ⁷. That paper sits alongside earlier Russian-language work on the antihypoxic properties of short peptides ³ and their biological activity in in vitro model experiments ¹.

Free radical suppression is the most conventional mechanism proposed for any compound in this family, and it does not require the DNA-binding hypothesis to be true.

Neurogenesis and gene expression

A 2021 review sets out the molecular-genetic aspects of KED’s proposed regulation of neurogenesis in Alzheimer’s disease ²³, with a companion review covering the related EDR peptide’s proposed regulation of gene expression and protein synthesis in the same disease ²². Short peptides affected neuronal differentiation of stem cells in work with an Italian group at Chieti-Pescara ²⁰, and protected fibroblast-derived induced neurons from age-related changes ²⁴. The tripeptide Lys-Glu-Asp affected the physiological activity of neuroimmunoendocrine system cells in organ culture ¹³, and peptides were reported to stimulate cell differentiation tissue-specifically during cellular ageing ¹².

The Alzheimer’s framing rests on two reviews from the developing group proposing mechanisms, not on any study in an Alzheimer’s model or patient.

Vascular

A 2016 Russian-language paper describes molecular aspects of KED’s vasoprotective activity in atherosclerosis and restenosis ¹⁹.

04 · Key research findings

Brain under hypoxic and ischaemic stress. Administration of short peptides before carotid artery occlusion affected behaviour and caspase-3 activity in the brains of old rats ⁵. Peptide geroprotectors affected navigation-system learning and caspase-3 in brain structures of rats of different ages ¹⁴. Pinealon and Cortexin affected behaviour and neurochemical processes in 18-month-old rats under hypoxia and hypothermia ¹⁷.

Three studies, one research group, all in Russian, all in the same journal, all using caspase-3 and behaviour as endpoints in stressed rat brain. The consistency reflects a single laboratory’s programme rather than independent convergence.

Prenatal hyperhomocysteinaemia. Pinealon protected rat offspring from prenatal hyperhomocysteinaemia, published in an English-language journal with the group that produced the cell viability work ¹⁰.

The most specific animal finding in the file, and one of only two indexed in English.

Cell viability and free radicals. Pinealon increased cell viability by suppressing free radical levels and activating proliferative processes ⁷.

Published in a journal with an international readership, with an author from outside the programme. It remains a single in vitro study.

Nuclear penetration. Short fluorescence-labelled peptides entered the nucleus in HeLa cells and bound deoxyribooligonucleotides and DNA specifically in vitro ⁸, with the physical chemistry of a related peptide–DNA interaction characterised independently ²¹.

The mechanistic spine of the whole programme, and the part most amenable to being tested by someone else — as, in the second case, it was.

Human reports. Peptide correction of neurotic disorders among professional truck drivers ¹¹, and the effect of synthetic peptides on ageing in patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission ¹⁶. Related Russian-language work examined biological age and adaptation in locomotive brigade workers ⁹ and compared geroprotective methods ¹⁸.

Four human-facing records, all Russian, none with an indexed abstract. This guide can report that they exist and what their titles say. It cannot report what they found, how many people took part, or whether anything was controlled.

Adjacent tetrapeptide work, listed here so it is not mistaken for Pinealon evidence. KEDG and Ala-Glu-Asp-Gly affected thyroid structure and function in neonatally hypophysectomised chickens ² and in hypophysectomised young chickens and old hens ⁶, and thymus morphology in hypophysectomised young and old birds ¹⁵. The biological activity of the tetrapeptide KEDW was studied separately ⁴.

Four papers that appear under Pinealon searches and are not about Pinealon.

Contemporary appraisal. A 2026 review of therapeutic peptides in gerontology surveys this class ²⁵.

05 · Evidence overview

06 · Safety profile

Animal data. No formal toxicology programme is identified. The rat studies use behavioural and biochemical endpoints under induced stress ^5,10,14,17 and were not designed to detect harm.

Human data. Two Russian-language reports exist ^11,16 and neither has been read for this guide. No adverse event information is available from the indexed record for this compound in any species.

What is genuinely unknown. Whether an administered tripeptide survives to reach any tissue: three residues is within the range cleaved rapidly by plasma and tissue peptidases, and nothing in this literature reports a plasma concentration or a half-life. Whether nuclear penetration observed with labelled peptide in a cultured cell line ⁸ occurs after dosing an animal. The specificity of the proposed DNA interaction, which for a three-residue peptide would be very low and is not quantified anywhere. What the compound does outside the brain, since almost every in vivo experiment is a neurological one. Repeat-dose toxicology, genotoxicity, reproductive toxicology and carcinogenicity: none performed — and reproductive toxicology is a specific gap, because the one distinctive animal result concerns administration during pregnancy in rats ¹⁰. Immunogenicity, unassessed. And the identity or purity of any commercial preparation, on which no published analysis exists.

07 · US regulatory status

Current as of 6 September 2026. Pinealon is not approved as a drug in the United States or the European Union and is not a controlled substance in the United States.

As with the other compounds in this programme, the substance has a history of use within the Russian medical system that this guide does not characterise, because doing so would require Russian regulatory records that have not been consulted. That question is logged.

Under the World Anti-Doping Code, substances not approved for human therapeutic use by any governmental regulatory health authority fall within class S0. Competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. The grade rests on two papers this guide has not read. PubMed tags one as a clinical trial ¹¹; the other is a titled report in the same Russian-language journal ¹⁶. Neither abstract is indexed. An Early Clinical grade assigned on that basis carries very little information, and Section 2 says so.
2. Ten of twenty-five references are Russian-language without indexed abstracts. For those records, this guide can report the title, the authors, the journal and nothing else. A reader cannot check the claims against the sources, and neither could the writer.
3. Publication is concentrated in one journal. Advances in Gerontology carries the majority of the Russian-language records here ^{1,3,5,9,11,14,16,17,18,19}. Concentration of this degree limits external scrutiny independently of the quality of any individual paper.
4. The animal evidence is one laboratory studying one organ under one kind of stress. Behaviour and caspase-3 in rat brain under ischaemia, hypoxia or hypothermia ^5,14,17. The results are consistent because they come from the same group asking the same question.
5. The mechanism has a specificity problem the literature does not address. A three-residue peptide binding DNA ^8,21 cannot distinguish among genomic sites in the way a transcription factor does. No paper estimates the number of binding sites, the affinity, or the occupancy that would be required for meaningful regulation.
6. Pharmacokinetics are absent for a molecule that should have difficult pharmacokinetics. Nothing demonstrates that intact Pinealon reaches a cell nucleus in a living animal.
7. Adjacent compounds contaminate the literature. KEDG, KEDW and EDR appear in the same searches and the same review articles ^2,4,6,15,22. Any summary of “Pinealon research” that does not separate them will overstate the evidence base, and several do not.
8. The Alzheimer’s disease framing is proposal, not result. Two reviews from the developing group set out molecular-genetic mechanisms by which KED and EDR might regulate neurogenesis and gene expression in Alzheimer’s disease ^22,23. No study in an Alzheimer’s model or in patients with the disease appears in the indexed record.
9. No randomised controlled trial exists in any species for any endpoint.
10. Nothing is known about commercial material. No published analysis has examined any product sold as Pinealon.

09 · References

1. Kozina LS. [Investigation of antihypoxic properties of short peptides]. Adv Gerontol. 2008;21(1):61–67. Russian.

   PMID 18546825 ↗

2. Kozina LS, Arutiunian AV, Stvolinskiĭ SL, Khavinson VKh. [Biological activity of regulatory peptides in model experiments in vitro]. Adv Gerontol. 2008;21(1):68–73. Russian.

   PMID 18546826 ↗

3. Kuznik BI, Pateyuk AV, Rusaeva NS. Effect of tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the structure and function of the thyroid gland in neonatally hypophysectomized chickens. Bull Exp Biol Med. 2008 Jan;145(1):104–107.

   PMID 19024016 ↗

4. Khavinson VKh, Gapparov MM, Sharanova NE, Vasilyev AV, Ryzhak GA. Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide. Bull Exp Biol Med. 2010 Sep;149(3):351–353.

   PMID 21246099 ↗

5. Mendzheritskiĭ AM, Karantysh GV, Ivonina KO. [Effects of introduction of short peptides before carotid artery occlusion on behaviour and caspase-3 activity in the brain of old rats]. Adv Gerontol. 2011;24(1):74–79. Russian.

   PMID 21809624 ↗

6. Kuznik BI, Pateyuk AV, Rusaeva NS, Baranchugova LM, Obydenko VI. Effects of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on hormonal activity and structure of the thyroid gland in hypophysectomized young chickens and old hens. Bull Exp Biol Med. 2011 Feb;150(4):495–499.

   PMID 22268052 ↗

7. Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res. 2011 Oct;14(5):535–541.

   PMID 21978084 ↗

8. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011 Nov;76(11):1210–1219.

   PMID 22117547 ↗

9. Nazimko VA, Morgul’ EV, Petrova OA, Sheĭkhova RG, Kozina LS, Savenko MA, Lysenko DS. [Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades]. Adv Gerontol. 2012;25(1):57–62. Russian.

   PMID 22708445 ↗

10. Arutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med. 2012;5(2):179–185.

    PMID 22567179 ↗

11. Bashkireva AS, Artamonova VG. [The peptide correction of neurotic disorders among professional truck-drivers]. Adv Gerontol. 2012;25(4):718–728. Clinical trial. Russian.

    PMID 23734521 ↗

12. Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012 May;153(1):148–151.

    PMID 22808515 ↗

13. Chalisova NI, Lopatina NG, Kamishev NG, et al. Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. Bull Exp Biol Med. 2012 Aug;153(4):569–572.

    PMID 22977872 ↗

14. Mendzheritski AM, Karantysh GV, Abramchuk VA, Ryzhak GA. [Effect of peptide geroprotectors on the navigation system learning and caspase-3 in brain structures in rats of different age]. Adv Gerontol. 2013;26(2):252–257. Russian.

    PMID 28976148 ↗

15. Pateyk AV, Baranchugova LM, Rusaeva NS, Obydenko VI, Kuznik BI. Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bull Exp Biol Med. 2013 Mar;154(5):681–685.

    PMID 23658898 ↗

16. Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE. [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission]. Adv Gerontol. 2015;28(1):62–67. Russian.

    PMID 26390612 ↗

17. Mendzheritsky AM, Karantysh GV, Ryzhak GA, Prokofiev VN. [Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia]. Adv Gerontol. 2015;28(3):532–539. Russian.

    PMID 28509493 ↗

18. Myakotnykh VS, Torgashov MN, Egorin KV, et al. [Comparative analysis of different methods of geroprotective]. Adv Gerontol. 2016;29(4):594–601. Russian.

    PMID 28539017 ↗

19. Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VK, Dyakonov MM, Kozina LS. [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]. Adv Gerontol. 2016;29(4):646–650. Russian.

    PMID 28539025 ↗

20. Caputi S, Trubiani O, Sinjari B, Trofimova S, Diomede F, Linkova N, Diatlova A, Khavinson V. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019 Jan–Dec;33:2058738419828613.

    PMID 30791821 ↗

21. Silanteva IA, Komolkin AV, Morozova EA, Vorontsov-Velyaminov PN, Kasyanenko NA. Role of mono- and divalent ions in peptide Glu-Asp-Arg-DNA interaction. J Phys Chem B. 2019 Mar 7;123(9):1896–1902.

    PMID 30762356 ↗

22. Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer’s disease. Molecules. 2020 Dec 31;26(1):159.

    PMID 33396470 ↗

23. Khavinson VK, Lin’kova NS, Umnov RS. Peptide KED: molecular-genetic aspects of neurogenesis regulation in Alzheimer’s disease. Bull Exp Biol Med. 2021 May;171(2):190–193. Review.

    PMID 34173097 ↗

24. Kraskovskaya N, Linkova N, Sakhenberg E, et al. Short peptides protect fibroblast-derived induced neurons from age-related changes. Int J Mol Sci. 2024 Oct 22;25(21):11363.

    PMID 39518916 ↗

25. Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging. 2026 Apr 7;7:1790247.

    PMID 42021992 ↗